The annual general meeting of Gentian Diagnostics ASA was held on 18 May 2022.
All the proposed resolutions on the agenda were approved in accordance with the
notice for the meeting, which were published on 27 April 2022. 

The minutes of the annual general meeting are enclosed. 

The board of directors now consist of 8 members of which the following were
re-elected: 

Tomas Settevik (Chair)
Espen Tidemann Jørgensen
Kari E. Krogstad
Susanne Stuffers
Tomas Kramar

The following persons were elected as new board members: 

Monika Neumann  
Monika Neuman has 20 years of experience from the diagnostics industry,
currently holding a position as Managing Director for Sarstedt Group in the
Nordics.  She has previously had several international and commercial leadership
roles like Head of Sales, EMEA , and VP Global Business Management. During the
past 4 years, Ms Neuman has been working at Siemens Healthineers Laboratory
Diagnostics headquarters in Tarrytown, NY, where she was closely collaborating
with R&D, Manufacturing, Marketing, and Customer Service to set a successful
strategy for launch and implementation of a new product portfolio on the global
IVD market. 

Ms Neuman holds a MSc degree in Biochemistry and a PhD degree in Clinical
Bacteriology from Medical Faculty at Göteborg University in Sweden.  

Fredrik Thoresen 
Fredrik Thoresen is a partner in Andenaesgruppen where he joined in 2021. Prior
to joining Andenaesgruppen, Mr. Thoresen worked as a Portfolio Manager at
Storebrand Asset Management and as an Equity Research Analyst at SEB. Mr.
Thoresen has also previous buy- and sell-side experience from DNB and Sector
Asset Management.
 
Mr. Thoresen has an MBA in International Business from Middlebury Institute of
International Studies, Monterey, California and a bachelor's degree in Computer
Science and Economics from Augustana University, Sioux Falls, South Dakota.

Frank Frantzen 
Frank Frantzen has more than 35 years of experience from the diagnostic
industry. He has served as principal scientist and has directed larger R&D units
in the international IVD companies Axis-Shield, Alere and Abbott. Mr. Frantzen
left his Senior Director R&D position at Abbott in 2021 and is currently serving
as Chief Technology Officer in CardiNor AS. 

Mr. Frantzen holds a master's degree in chemistry and a Ph.D. in
chemistry/biotechnology/IVD-technology, both from the Norwegian University of
Science and Technology in Trondheim.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

IR Contact: 
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.com
Cell phone: +47 919 06 525